Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats

Toshiaki Sendo, Takeshi Goromaru, Keisei Aki, Naoko Sakai, Yoshinori Itoh, Ryozo Oishi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The effects of carbazochrome sodium sulfonate (AC-17), a capillary stabilizer, on pulmonary edema and dysfunction induced by ioxaglate, an ionic radiographic contrast medium, were evaluated in rats. The pulmonary edema was evaluated by the extravasation of intravenously injected Evans blue into lung tissues, while pulmonary dysfunction was determined by monitoring blood gasses including pO 2. Ioxaglate (4 g I/kg, i.v.) caused a marked increase in vascular permeability and a decrease in arterial pO 2. AC-17 reversed the ioxaglate-induced vascular hyperpermeability in a dose-dependent manner. In addition, AC-17 (10 mg/kg) significantly inhibited the decrease in arterial pO 2. In isolated rat pulmonary mast cells, ioxaglate markedly enhanced the histamine release, which was not affected by AC-17. On the other hand, AC-17 did significantly blocked the hyperpermeability induced in cultured bovine endothelial cells by tryptase, thrombin and proteinase-activated receptor-2 agonist peptide (SLIGKV-NH 2). These findings suggest that AC-17 blocks radiographic contrast medium-induced pulmonary dysfunction by maintaining the endothelial barrier function. Thus, the compound is potentially useful for the prophylaxis of contrast media-induced acute pulmonary adverse events during angiography.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalEuropean Journal of Pharmacology
Volume450
Issue number2
DOIs
Publication statusPublished - Aug 23 2002
Externally publishedYes

Fingerprint

Contrast Media
Ioxaglic Acid
Lung
seryl-leucyl-isoleucyl--glycyl-lysyl-valine
Pulmonary Edema
PAR-2 Receptor
Tryptases
Evans Blue
Histamine Release
Capillary Permeability
carbazochrome
Mast Cells
Thrombin
Blood Vessels
Angiography
Endothelial Cells
Peptides

Keywords

  • Carbazochrome
  • Endothelial barrier function
  • Evans blue
  • Pulmonary edema
  • Radiographic contrast media
  • Vascular permeability

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. / Sendo, Toshiaki; Goromaru, Takeshi; Aki, Keisei; Sakai, Naoko; Itoh, Yoshinori; Oishi, Ryozo.

In: European Journal of Pharmacology, Vol. 450, No. 2, 23.08.2002, p. 203-208.

Research output: Contribution to journalArticle

Sendo, Toshiaki ; Goromaru, Takeshi ; Aki, Keisei ; Sakai, Naoko ; Itoh, Yoshinori ; Oishi, Ryozo. / Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. In: European Journal of Pharmacology. 2002 ; Vol. 450, No. 2. pp. 203-208.
@article{49ae7d654fe642d88df96af71fb37101,
title = "Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats",
abstract = "The effects of carbazochrome sodium sulfonate (AC-17), a capillary stabilizer, on pulmonary edema and dysfunction induced by ioxaglate, an ionic radiographic contrast medium, were evaluated in rats. The pulmonary edema was evaluated by the extravasation of intravenously injected Evans blue into lung tissues, while pulmonary dysfunction was determined by monitoring blood gasses including pO 2. Ioxaglate (4 g I/kg, i.v.) caused a marked increase in vascular permeability and a decrease in arterial pO 2. AC-17 reversed the ioxaglate-induced vascular hyperpermeability in a dose-dependent manner. In addition, AC-17 (10 mg/kg) significantly inhibited the decrease in arterial pO 2. In isolated rat pulmonary mast cells, ioxaglate markedly enhanced the histamine release, which was not affected by AC-17. On the other hand, AC-17 did significantly blocked the hyperpermeability induced in cultured bovine endothelial cells by tryptase, thrombin and proteinase-activated receptor-2 agonist peptide (SLIGKV-NH 2). These findings suggest that AC-17 blocks radiographic contrast medium-induced pulmonary dysfunction by maintaining the endothelial barrier function. Thus, the compound is potentially useful for the prophylaxis of contrast media-induced acute pulmonary adverse events during angiography.",
keywords = "Carbazochrome, Endothelial barrier function, Evans blue, Pulmonary edema, Radiographic contrast media, Vascular permeability",
author = "Toshiaki Sendo and Takeshi Goromaru and Keisei Aki and Naoko Sakai and Yoshinori Itoh and Ryozo Oishi",
year = "2002",
month = "8",
day = "23",
doi = "10.1016/S0014-2999(02)02120-9",
language = "English",
volume = "450",
pages = "203--208",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats

AU - Sendo, Toshiaki

AU - Goromaru, Takeshi

AU - Aki, Keisei

AU - Sakai, Naoko

AU - Itoh, Yoshinori

AU - Oishi, Ryozo

PY - 2002/8/23

Y1 - 2002/8/23

N2 - The effects of carbazochrome sodium sulfonate (AC-17), a capillary stabilizer, on pulmonary edema and dysfunction induced by ioxaglate, an ionic radiographic contrast medium, were evaluated in rats. The pulmonary edema was evaluated by the extravasation of intravenously injected Evans blue into lung tissues, while pulmonary dysfunction was determined by monitoring blood gasses including pO 2. Ioxaglate (4 g I/kg, i.v.) caused a marked increase in vascular permeability and a decrease in arterial pO 2. AC-17 reversed the ioxaglate-induced vascular hyperpermeability in a dose-dependent manner. In addition, AC-17 (10 mg/kg) significantly inhibited the decrease in arterial pO 2. In isolated rat pulmonary mast cells, ioxaglate markedly enhanced the histamine release, which was not affected by AC-17. On the other hand, AC-17 did significantly blocked the hyperpermeability induced in cultured bovine endothelial cells by tryptase, thrombin and proteinase-activated receptor-2 agonist peptide (SLIGKV-NH 2). These findings suggest that AC-17 blocks radiographic contrast medium-induced pulmonary dysfunction by maintaining the endothelial barrier function. Thus, the compound is potentially useful for the prophylaxis of contrast media-induced acute pulmonary adverse events during angiography.

AB - The effects of carbazochrome sodium sulfonate (AC-17), a capillary stabilizer, on pulmonary edema and dysfunction induced by ioxaglate, an ionic radiographic contrast medium, were evaluated in rats. The pulmonary edema was evaluated by the extravasation of intravenously injected Evans blue into lung tissues, while pulmonary dysfunction was determined by monitoring blood gasses including pO 2. Ioxaglate (4 g I/kg, i.v.) caused a marked increase in vascular permeability and a decrease in arterial pO 2. AC-17 reversed the ioxaglate-induced vascular hyperpermeability in a dose-dependent manner. In addition, AC-17 (10 mg/kg) significantly inhibited the decrease in arterial pO 2. In isolated rat pulmonary mast cells, ioxaglate markedly enhanced the histamine release, which was not affected by AC-17. On the other hand, AC-17 did significantly blocked the hyperpermeability induced in cultured bovine endothelial cells by tryptase, thrombin and proteinase-activated receptor-2 agonist peptide (SLIGKV-NH 2). These findings suggest that AC-17 blocks radiographic contrast medium-induced pulmonary dysfunction by maintaining the endothelial barrier function. Thus, the compound is potentially useful for the prophylaxis of contrast media-induced acute pulmonary adverse events during angiography.

KW - Carbazochrome

KW - Endothelial barrier function

KW - Evans blue

KW - Pulmonary edema

KW - Radiographic contrast media

KW - Vascular permeability

UR - http://www.scopus.com/inward/record.url?scp=0037162711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037162711&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(02)02120-9

DO - 10.1016/S0014-2999(02)02120-9

M3 - Article

C2 - 12206859

AN - SCOPUS:0037162711

VL - 450

SP - 203

EP - 208

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -